Sort by
Search results
uPA (Urokinase Plasminogen activator)
Recommended for all research protocols where a source of purified urokinase is required. Can be used for the assay of human plasminogen. Activates plasminogen to generate plasmin.
Kallikrein, Human, gereinigt
Kallikrein, human, purified (Plasma)
Kininogen Deficient Plasma, frozen
For any in vitro protocol or research study where a source of human kininogen deficient plasma is required.
Imidazole buffer pH 7.30
Buffer for clotting assays (plasma samples). Diluent for plasma
Imidazole buffer pH 7.30
Buffer for clotting assays (plasma samples). Diluent for plasma
BIOPHEN Heparin LRT 3 (Liquid Reagent Technology)
Measuring the concentration of UFH, LMWH, Arixtra ® , Orgaran ® , rivaroxaban (Xarelto ® ), apixaban (Eliquis ® ) and edoxaban (Lixiana ® ) in patients’ plasma for monitoring the therapy and adjusting drug dosage.
BIOPHEN Heparin LRT 7.5 (Liquid Reagent Technology)
Measuring the concentration of UFH, LMWH, Arixtra ® , Orgaran ® , rivaroxaban (Xarelto ® ), apixaban (Eliquis ® ) and edoxaban (Lixiana ® ) in patients’ plasma for monitoring the therapy and adjusting drug dosage.
CEPHEN APTT LS 2.5 (Lupus Sensitive)
Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.
CEPHEN APTT 1
Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.
CEPHEN APTT 2.5
Measurement of the plasma recalcification time, in presence of the standardized aPTT (activated partial thromboplastin time) reagent (cephalin and activator), on human citrated plasma, to explore the activity of the intrinsic pathway coagulation factors (II, V, VIII, IX, X, XI, XII) and “anticoagulant” activities.